Alder Biopharmaceuticals, the Bothell, WA-based maker of antibody drugs, was honored today as one of the nation’s 15 most promising biotech companies, in the annual Fierce 15 list published by FierceBiotech. Alder emerged from the ashes of Celltech R&D back in 2003 to secure a billion-dollar partnership last year from Bristol-Myers Squibb to develop a new drug for rheumatoid arthritis. Alder was the only Seattle-area biotech company to make the list this year. Last year’s class of 15 included Seattle-based Calistoga Pharmaceuticals.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
